Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of 5637 Cell Line Based Bladder Cancer (CAT#: STEM-AE-0002-LGZ)

Introduction

Bladder cancer is a malignant tumor occurring on the mucous membrane of the bladder. It is the most common malignant tumor of the urinary system and one of the ten most common tumors of the whole body. The etiology of bladder cancer is complex, with both internal genetic factors and external environmental factors. Two clear risk factors are smoking and occupational exposure to aromatic amines. Smoking is the most certain risk factor for bladder cancer at present, 30% ~ 50% of bladder cancer is caused by smoking, smoking can increase the risk of bladder cancer by 2 ~ 6 times, with the extension of smoking time, the incidence of bladder cancer is significantly increased. Another important risk factor is associated with a range of occupations or occupational exposures.




Principle

In vivo activity is the gold standard for the evaluation of drug biological activity, and it is the first verification of non-human comprehensive activity. In vivo pharmacodynamic evaluation plays a decisive role in the confirmation of candidate molecules and the screening of clinical target indications, and is an indispensable link in the development of new drugs. We provide a variety of disease animal models including inflammation, immunity, metabolism, etc., to meet the needs of different new drug research and development projects of customers, and accept customized services.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.

Applications

Bladder Cancer

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder

Notes

Oncology efficacy Service package:
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model
Advertisement